Introduction: The varied results of studies about oral cilostazol in improving mean walking distance of patients with intermittent claudication were controversial. In this study, we will report the meta-analysis of oral cilostazol in the management of intermittent claudication in peripheral arterial disease. The parameters that will be carried out was mean walking distance.
INTRODUCTION
Peripheral artery disease (PAD) is a progressive atherosclerotic disorder that can lead to poor quality of life, an increased risk of disabilities, cost burden, and mortality. [1] [2] The number of cases worldwide was estimated to increase by around one-quarter to approximately 200 million in the last 10 years. 3 Low income countries dominated the cases, especially in Southeast Asia and Western Pacific regions. 4 About 30% of arterial occlusive disease was infrapopliteal lesions of the patients with PAD. 5 Platelets have a fundamental role in the development of atherothrombosis. Although percutaneous revascularization therapies have evolved significantly with dramatic improvement in interventional devices and techniques, the most appropriate antiplatelet therapy regimen in PAD is understudied. 6 Cilostazol was approved by the FDA in 1999 for reducing the symptoms of intermittent claudication. In four US Phase III multicenter, randomized, blinded trials, over 1500 claudicants were administered cilostazol over a 12-24 week period. Across these studies, the range of improvement in MWD in patients treated with cilostazol 100 mg twice daily compared with placebo. 7 In this study, we will report the meta-analysis of oral cilostazol in the management of intermittent claudication in peripheral arterial disease. The parameters that will be carried out was mean walking distance.
METHODS

Data collection
This study presents a meta-analysis of oral cilostazol in the management of intermittent claudication in peripheral arterial disease. The study design follows the PRISMA guidelines for meta-analysis. The steps follow the Cochrane Handbook for Systematic Review of Interventions guidelines.
Comprehensive literature search was done in Medline and SCOPUS. References from all studies are further reviewed to identify additional relevant research. There will be no initial limit on the date of publication. We will search for publications with medical subject headings (MeSH) and keywords in title, abstract and text for cilostazol, intermittent claudication, and peripheral arterial disease.
Data screening
Titles and abstracts of all searched and referenced papers were initially screened to obtain the eligible full-text articles. Exclusion criteria were studies in which vessels treated were limited to the infrapopliteal arteries. Studies without a clear report of outcomes, case reports, and reviews were also excluded. The parameters that will be carried out were cilostazol, intermittent claudication, and peripheral arterial disease. If there is more than one publication from the same study, we will only include the latest publication. Further studies may be included through searching reference lists in publications selected for the review.
Data extraction
Duplicate journals are managed using EndNote. The title and abstract of the search results are reviewed and the full text is analysed for inclusion in this meta-analysis. All articles are assessed using the inclusion and exclusion criteria determined by the author. The eligible studies to be screened in this meta-analysis was the study which provide the proportion of the parameters in this study, either all of parameters or even single parameter. However, we limit the study which had a control group. We excluded any study without full text and included only English-text articles. From the selected publications, we will extract where available: name of the study;
year of study; length of follow-up; and the rate of binary restenosis, target lesion revascularization, amputation, and mortality rate.
Data analysis
The statistical analysis was performed in Review Manager (RevMan V.5.3, The Cochrane Collaboration) or Stata version 13. Given the clinical heterogeneity of the included studies, random-effects models were used to pool data. Statistical heterogeneity was assessed using the I 2 statistic. Binary dichotomous outcomes for each study were pooled as odds ratio (RR). In this meta-analysis, the pooled proportion were analyzed and compared with Z test. Meta-analysis results were reported as proportion and 95% CIs. The funnel plots would be described in the results section. A two-tailed p value of ≤0.05 was considered statistically significant. Other assessments of heterogeneity will include I 2 (I 2 ≥75% equates to high heterogeneity 14 ) and visual inspection of the forest plot for inconsistencies in effect sizes and their confidence intervals.
RESULTS
In this meta-analysis, seven studies (Table 1) were included after applying PRISMA principle (Figure 1) . It was shown a significant difference (improvement) of mean walking distance in cilostazol therapy than placebo. The mean walking distance was improved by 51 meters, concluding that this drug was effective in achieving decrement of pain symptoms thus increase the quality of life ( Figure 2 ). 
DISCUSSION
Cilostazol is a 2-quinolinone compound, the medication suppresses cyclic adenosine monophosphate (cAMP) degradation via phosphodiesterase III inhibition. Consequently, the level of cAMP in platelets and blood vessels is increased, leading to inhibition of platelet aggregation and to vasodilation, respectively. Cilostazol exhibits dose-responsive benefit. In recommendation, Cilostazol is an effective therapy to improve symptoms and increase walking distance in patients with claudication. With the level of IA. 8 The majority of patients with intermittent claudication are treated with best medical management. Symptoms of intermittent claudication, walking distance, and quality of life can be improved by risk factor modification, which includes smoking cessation and a structured exercise programme. Further cardiovascular risk modification includes treatment for hypertension, diabetes and cholesterol reduction. In practice, compliance with best medical treatment is poor and most people continue to have symptoms of intermittent claudication. Some drug therapies are used specifically to help improve walking distance in intermittent claudication and cilostazol is one of these. 15 In this meta-analysis, it was shown a significant difference (improvement) of mean walking distance in cilostazol therapy than placebo. The mean walking distance was improved by 51 metres, concluding that this drug was effective in achieving decrement of pain symptoms thus increase the quality of life. It is unclear exactly how cilostazol works to improve claudication, but the mechanism is most likely multifactorial, involved with several of cilostazol's actions, specifically vasodilation, possible beneficial inhibition of platelet aggregation and altering lipid profile. 16 However, a black box warning indicates that cilostazol should be avoided in patients with congestive heart failure. The warning does not specify the heart failure classification or the degree of severity that should be avoided. This warning was imposed by the FDA because of the prior experience of chronic oral milrinone therapy (another PDE-III inhibitor) in patients with heart failure. 17 We noticed a considerable variability in study design, eligibility criteria for patient enrollment, and outcome end points among RCTs. The comorbidities of arterial diseases in the studies were not well controlled and sometimes overlapped with venous disease. Furthermore, the parameters results were inconsistently reported among the trials, with some of them reporting clinically driven revascularization.
CONCLUSION
There was a significant difference (improvement) of mean walking distance in cilostazol therapy than placebo. Advances in the fields of molecular biology and genetic engineering have made it possible to develop new antithrombotic agents and optimize drug selection in patients.
